Every 3 minutes, a mother dies. Every minute, 2 newborns die in the WHO African Region.
These deaths are not all caused by PPH or by lack of donor blood. But severe postpartum hemorrhage exposes the system at its weakest point: blood, donor blood availability, transfusion infrastructure, transport and emergency care must work in time.
Every mother matters. Every child matters. We believe more of these lives can be saved.
PPH is not a knowledge problem alone. It is speed, donor blood, patient blood management, transfusion infrastructure and implementation.
Modern obstetric care has effective PPH treatments. Patient blood management (PBM), compatible donor blood, functioning blood banks, transfusion infrastructure, trained teams, transport and definitive care all matter when severe bleeding develops.
Bleeding is visible. Tissue hypoxia is the downstream threat.
PPH management must stop the bleeding first. Severe blood loss also reduces perfusion and oxygen-carrying capacity, making tissue oxygen delivery a critical physiological endpoint.
- Haemorrhage control remains primary.
- PBM, transfusion and blood components remain part of current standard care when indicated and available.
- Any future oxygen-delivery therapeutic would need product-specific evidence and should be evaluated as a complement, not a universal blood replacement.
Where the treatment gap appears.
Existing programs first. Innovation second.
Current priorities include faster diagnosis, uterotonics, tranexamic acid, bundled treatment, patient blood management (PBM), stronger blood banks, donor blood and transfusion capacity, and emergency transport.
Educational evidence page. The maternal mortality figures describe all maternal causes, not PPH alone. The headline rates use WHO African Region estimates of about 20 maternal deaths and 120 newborn deaths per hour - approximately one maternal death every three minutes and two newborn deaths every minute. These deaths are not presented as being caused solely by PPH or by lack of donor blood. BHOC relevance is a research hypothesis, not a claim of approved treatment or demonstrated clinical benefit.